Examination of Class I HLA-Fc Fusion Proteins in Targeting Cognate Antibody-Producing Cells.

Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

Despite major progress with chimeric antigen receptor (CAR) T-cell therapy, multiple myeloma (MM) remains largely incurable, and most patient relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig)...

CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II Alleles.

Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target lineage-specific surface antigens. However, CAR T cells show limited efficacy against myeloid neoplasms and solid tumors due to challenges in identifying suitable surface tar...

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens

ABSTRACT Redirection of T lymphocytes toward cancer cells has been one of the most promising treatment concepts in oncology developed over the past years and leading to multiple regulatory approvals for both adoptive cell therapy (ACT) and T-cell-engaging bispecific (TEB) molecules. However, progress has been achieved...

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

The biology, disease-associated functions, and therapeutic targeting of nonclassical MHC-I molecules are synthesized, integrating immune checkpoint blockade, antibody-based therapeutics, and MR1- and CD1-restricted cellular immunotherapies into a unified framework.

Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide–HLA complex

An integrated platform for generating human antibodies that mimic T-cell receptors and recognize peptide-HLA complexes with high specificity and affinity is developed, demonstrating superior performance compared to competitors’ TCRm antibodies.